Precision BioSciences, Inc. (NASDAQ:DTIL) Director Geno J. Germano Acquires 3,250 Shares

Precision BioSciences, Inc. (NASDAQ:DTIL) Director Geno J. Germano acquired 3,250 shares of the firm’s stock in a transaction that occurred on Tuesday, March 25th. The shares were bought at an average cost of $5.30 per share, for a total transaction of $17,225.00. Following the purchase, the director now owns 11,057 shares of the company’s stock, valued at approximately $58,602.10. The trade was a 41.63 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Precision BioSciences Stock Up 3.5 %

DTIL opened at $4.70 on Friday. Precision BioSciences, Inc. has a 12 month low of $3.61 and a 12 month high of $15.97. The business has a 50-day moving average of $5.11 and a two-hundred day moving average of $6.55. The company has a debt-to-equity ratio of 0.34, a current ratio of 9.22 and a quick ratio of 9.22. The stock has a market capitalization of $36.05 million, a price-to-earnings ratio of 78.35 and a beta of 1.59.

Precision BioSciences (NASDAQ:DTIL) last issued its quarterly earnings results on Wednesday, March 26th. The company reported ($3.20) EPS for the quarter, missing the consensus estimate of ($2.09) by ($1.11). The company had revenue of $3.47 million for the quarter, compared to analyst estimates of $4.28 million. Precision BioSciences had a negative return on equity of 23.69% and a net margin of 11.48%. On average, research analysts expect that Precision BioSciences, Inc. will post -1.23 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Lynx1 Capital Management LP acquired a new stake in Precision BioSciences during the fourth quarter worth about $2,919,000. Janus Henderson Group PLC grew its holdings in shares of Precision BioSciences by 10.9% during the 3rd quarter. Janus Henderson Group PLC now owns 702,069 shares of the company’s stock worth $6,322,000 after purchasing an additional 68,943 shares during the period. Citadel Advisors LLC increased its position in Precision BioSciences by 58.0% during the 4th quarter. Citadel Advisors LLC now owns 153,675 shares of the company’s stock worth $586,000 after purchasing an additional 56,400 shares in the last quarter. Moloney Securities Asset Management LLC raised its holdings in Precision BioSciences by 177.0% in the fourth quarter. Moloney Securities Asset Management LLC now owns 87,799 shares of the company’s stock valued at $335,000 after buying an additional 56,100 shares during the period. Finally, Dimensional Fund Advisors LP acquired a new position in Precision BioSciences during the fourth quarter valued at approximately $211,000. Institutional investors and hedge funds own 37.99% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on DTIL. BMO Capital Markets upgraded shares of Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 price target for the company in a report on Friday, January 10th. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 target price on shares of Precision BioSciences in a research note on Friday.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.